Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Study Shows Norvir, AZT, 3TC Regimen Renders Patients Aviremic VANCOUVER, July 11, 1996 -- A triple therapy regimen of the protease inhibitor Norvir(R) and the nucleoside analogues AZT and 3TC has rendered nine HIV-infected patients aviremic, as determined by culture and plasma RNA measurements, according to research presented here today at the 11th International Conference on AIDS. In the study, which is being conducted by investigators at the Aaron Diamond AIDS Research Center in New York, 12 patients newly infected with the HIV virus received a three-drug regimen consisting of 600 mg Norvir twice daily, 200 mg AZT three times daily, and 150 mg 3TC twice daily, beginning within 90 days of infection. Baseline plasma RNA for all 12 patients was 91,389 RNA copies/ml plasma at the initiation of therapy. Patients have been followed for various lengths of time, ranging from 90 days to 300 days, depending on when they began the, regimen. One patient withdrew from the study due to intolerance to all three drugs; while two non-compliant patients elected to discontinue therapy. At the furthest point of data collection for each of the nine patients remaining on the regimen, all patients are aviremic by PBMC co-culture, plasma culture and RNA determinations. Therapy is planned to continue for a minimum of one year, at which time lymphatic tissue will be obtained and assessed for active HIV replication. "Early results indicate that the regimen of Norvir, AZT and 3TC has rendered nine patients newly infected with HIV aviremic,'' said Martin Markowitz, M.D., of the Aaron Diamond Center, who is the lead investigator on the study. ``While this is very encouraging news, it's important to note that these results cannot yet be called a cure. We don't know if the virus will rebound if patients were to cease the regimen. Studies are underway to find an answer to this question.'' Norvir, manufactured byAbbott Laboratories, was cleared by the U.S, Food and Drug Administration March 1, 1996, for the treatment of HIV infection. E-mail this page to a friend or colleague! To print, use this version